Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Direct oral anticoagulants (DOACs) are established for stroke prevention in non-valvular atrial fibrillation (AF) and venous thromboembolism (VTE).
• Current guidelines restrict DOACs primarily to these approved indications.
• Emerging data suggest off-label efficacy in other thromboembolic conditions.

Purpose of the Study:

• To review the current evidence for direct oral anticoagulant use.
• To highlight the limitations of current guidelines regarding DOAC applications.
• To identify patient populations, such as those with valvular or prosthetic conditions, not yet adequately addressed by DOACs.

Main Methods:

• Literature review of existing studies on direct oral anticoagulants.
• Analysis of guideline recommendations for DOACs.
• Identification of off-label DOAC applications and unmet clinical needs.

Main Results:

• DOACs demonstrate safety and efficacy in approved indications (non-valvular AF, VTE, pulmonary embolism).
• Off-label use shows encouraging results for intracardiac thrombi, left ventricular thrombi, and left atrial appendage management.
• Valvular and prosthetic patients remain a largely unaddressed population for DOACs.

Conclusions:

• Direct oral anticoagulants have a broader potential therapeutic scope than currently recommended.
• Expanded DOAC use in specific patient groups requires further investigation and guideline updates.
• Future research should focus on evaluating DOACs in valvular and prosthetic heart disease patients.